Jesse Siegel, Pharm D
About Jesse Siegel, Pharm D
Jesse Siegel, Pharm.D., is the Associate Director and Senior Clinical Scientist at Bristol Myers Squibb in New Jersey, with extensive experience in oncology clinical research and development.
Current Role at Bristol Myers Squibb
Jesse Siegel, Pharm D, is currently serving as an Associate Director - Senior Clinical Scientist at Bristol Myers Squibb in New Jersey, United States. In this role, he is involved in high-level clinical research and development, particularly focusing on novel oncology treatments. He utilizes his extensive background in clinical science to contribute significantly to the development of new cancer therapies for patients.
Previous Experience at Merck
Jesse Siegel worked at Merck in various roles from 2017 to 2020. He served as Oncology-Senior Clinical Scientist for one year in the Greater New York City Area and was involved in Clinical Science & Study Management (CSSM) - Oncology in Rahway, New Jersey, for three years. During his tenure at Merck, he gained expertise in advancing PD1/PD-L1, HIF2a inhibitors, and Antibody Drug Conjugates (ADC) in phase Ib- phase III oncology clinical research.
Postdoctoral Fellowship at Rutgers
Jesse Siegel undertook a postdoctoral fellowship at Rutgers Pharmaceutical Industry Fellowship Program from 2017 to 2020. This program, based in Piscataway, New Jersey, provided him with in-depth training and hands-on experience in pharmaceutical industry practices, further enhancing his clinical research skills and knowledge.
Education and Credentials
Jesse Siegel earned his Doctor of Pharmacy (Pharm.D.) degree from Fairleigh Dickinson University, School of Pharmacy and Health Sciences, where he studied from 2013 to 2017. His education equipped him with strong foundational knowledge and skills in pharmacy, research, and clinical sciences.
Key Projects and Clinical Research
Jesse Siegel has led several significant clinical research projects. Notably, he was the Lead Clinical Scientist for the novel antibody drug conjugate (ADC), MORAb 202, and the CheckMate 9ER study. His work in these areas highlights his expertise in advancing clinical research and development in oncology, aiming to produce effective cancer therapies.